[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342725-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-342725-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","diagnostic-challenge-and-survival-analysis-of-pulmonary-oligometastases-and-primary-lung-cancer-in-breast-cancer-patients","Diagnostic challenge and survival analysis of pulmonary oligometastases and primary lung cancer in breast cancer patients","","Background compares breast cancer patients with pulmonary oligometastases (POM) versus primary lung cancer (PLC), evaluating differences in clinical and CT features and survival outcomes. Methods review 437 records (2010–2021) of malignant pulmonary nodules in breast cancer patients, identifying 45 POM and 43 PLC cases after initial nodule detection. Results link POM with advanced breast stage, higher grade, lower luminal-type proportion, and higher serum CYFRA 21-1, while PLC aligns with subsolid CT components, lobulation, air bronchogram, and pleural indentation, with higher 10-year survival for PLC. Conclusions propose CYFRA 21-1 and late-stage disease for POM diagnosis; CT indicators favor PLC.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/diagnostic-challenge-and-survival-analysis-of-pulmonary-oligometastases-and-primary-lung-cancer-in-breast-cancer-patients/342725/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/diagnostic-challenge-and-survival-analysis-of-pulmonary-oligometastases-and-primary-lung-cancer-in-breast-cancer-patients/342725.png","ImageObject",300,407,{"name":42,"@type":43},"Emma Wilson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-09-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":22},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What is the main aim of this study?","Question",{"text":62,"@type":63},"To compare breast cancer patients with pulmonary oligometastases (POM) versus primary lung cancer (PLC) and evaluate differences in clinical features, CT features, and survival outcomes.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How were POM and PLC identified in the study?",{"text":67,"@type":63},"Clinical records from 2010–2021 were reviewed for malignant pulmonary nodules in breast cancer patients, with POM identified in 45 patients and PLC in 43 after initial pulmonary nodule detection.",{"name":69,"@type":60,"acceptedAnswer":70},"Which findings on blood tests and CT imaging help distinguish POM from PLC?",{"text":71,"@type":63},"Higher serum CYFRA 21-1 and late-stage breast cancer support POM, while PLC is suggested by CT subsolid component, lobulation, air bronchogram, and pleural indentation.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},342725,1790154599,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":22,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","DOI: 10.1111/1759-7714.15285  \nORIGINA L ARTICLE  \nDiagnostic challenge and survival analysis of pulmonary  \noligometastases and primary lung cancer in breast cancer patients  \nSiyao Mai 1 | Haiqing Liu 1 | Hong Zeng 2 | Ziliang Cheng 1 | Jingwen Huang 1 | Guangzi Shi 1 | Yong Li 1 | Zhuo Wu 1   \n1Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China  \n2Department of Pathology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China  \nCorrespondence  \nZhuo Wu, Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, No. 107 Yanjiang Road West, Guangzhou 510120, Guangdong, China. [Email:](Email: wuzhuo@mail.sysu.edu.cn)[ wuzhuo@mail.sysu.edu.cn](Email: wuzhuo@mail.sysu.edu.cn)  \nFunding information  \nNational Natural Science Foundation of China, Grant/Award Number: 82271950; National Key Research and Development Program of China, Grant/Award Number: 2017YFC1309100  \nAbstract  \nBackground: The aim of this study was to compare breast cancer patients with pulmonary oligometastases (POM) and primary lung cancer (PLC) and to assess whether there were differences in clinical features, CT features, and survival outcomes between the two groups.  \nMethods: From January 2010 to December 2021, the clinical records of 437 with malignant pulmonary nodules who had breast cancer patients were reviewed. POM was identified in 45 patients and PLC in 43 patients after the initial detection of pulmonary nodules. The clinicopathological characteristics, CT appearance of pulmonary nodules, and survival of the two groups were compared.  \nResults: Stage II to IV breast tumors (p \u003C 0.001), high pathological grade of breast cancer (p = 0.001), low proportion of luminal-type breast cancer (p = 0.003), and the higher serum CYFRA 21-1 level (p = 0.046) were the clinical characteristics of pulmonary nodules suggestive of POM rather than PLC. The CT features of lung nodules indicative of PLC rather than POM were the subsolid component (p \u003C 0.001), lobulation (p = 0.010), air bronchogram (p \u003C 0.001) and pleural indentation (p = 0.004) . Ten-year survival rate for PLC was 93.2%, which was higher compared with 57.8% in those with POM (p = 0.001) .  \nConclusions: Elevated serum CYFRA 21-1 levels and late-stage breast cancer may be beneficial for the diagnosis of POM. CT imaging appearances of the subsolid component, lobulation, air bronchogram, and pleural indentation increase the likelihood of PLC. Breast cancer patients with PLC presented better survival with attentive monitoring than those with POM.  \nKEYW ORD S  \nbreast cancer, primary lung cancer, pulmonary oligometastases, second primary malignant neoplasms  \nINTRODUCTION  \nBreast cancer has surpassed lung cancer as the most common cancer in the world, 1,2 demonstrating that breast cancer has evolved into a major disease that endangers human women’s health. With the continuous progress of individualized treatment of breast cancer, the overall 5-year survival rate for women has reached 90% .3 However, the prognosis for metastatic breast cancer is poor with a 3-year overall survival rate of only 37 . 5% in patients with lung metastasis.4 The longer life period for many breast cancer patients has  \nled to an increase in the incidence rate of secondary malignancies, the most prevalent of which is lung cancer.5 The 5-year survival rate of patients with primary lung cancer is only 21%,3 which is substantially lower than that of patients with breast cancer but is comparable with the survival rate of those diagnosed with lung metastasis. The lung is one of the most common distant metastatic sites in patients with breast cancer,6 and benign lung nodules are frequently discovered concurrently in breast cancer patients during follow-up. Determining if lung nodules found during followup are pulmonary metastases (POM) or primary lung cancer  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial ","cbCaiinWZcTrbRf4","https://ap.wps.com/l/cbCaiinWZcTrbRf4","pdf",2109539,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is the main aim of this study?\",\"answer\":\"To compare breast cancer patients with pulmonary oligometastases (POM) versus primary lung cancer (PLC) and evaluate differences in clinical features, CT features, and survival outcomes.\"},{\"question\":\"How were POM and PLC identified in the study?\",\"answer\":\"Clinical records from 2010–2021 were reviewed for malignant pulmonary nodules in breast cancer patients, with POM identified in 45 patients and PLC in 43 after initial pulmonary nodule detection.\"},{\"question\":\"Which findings on blood tests and CT imaging help distinguish POM from PLC?\",\"answer\":\"Higher serum CYFRA 21-1 and late-stage breast cancer support POM, while PLC is suggested by CT subsolid component, lobulation, air bronchogram, and pleural indentation.\"}]","Diagnostic challenge and survival analysis of pulmonary oligometastases and primary lung cancer in breast cancer patients | PDF",1790047890]